---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094440"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2026-08-12T11:03:08+00:00"
generated_at: "2026-08-12T11:05:07.512750+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Humacyte Q2: Symvess sales up, net loss $36.8M; V012 Phase 3 hits primary endpoint

## Summary
- Q2 2026 Symvess sales $0.4M vs $0.1M prior year; net loss $36.8M vs $37.7M.
- V012 Phase 3 interim: ATEV beat AV fistula, 91 more catheter-free days (p=0.0007), infections 6 vs 23/100 pt-yrs.
- Plans sBLA for dialysis access with FDA in H2 2026; FDA accepted IND for CTEV in CABG, Phase 2a expected Q3 2026.
- Raised $57.5M gross in June public offering; restructuring cuts ~45 staff, saving ~$14.3M in 2026.
- Cash $80.3M at 6/30/26; six-month net loss $54.4M vs net income $1.5M year ago.

## SEC filing metadata
- accession: 0001104659-26-094440
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2026-08-12T11:03:08+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/0001104659-26-094440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/tm2622949d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094440
- JSON: https://secwatch.observer/filing/0001104659-26-094440.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094440.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.